Business
The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
On the back of a $135 million public offering in February, rare disease gene therapy company Krystal Biotech has launched subsidiary Jeune Inc. to promote its gene therapies for aesthetic skin conditions.
In a stunning fall from grace playing out this week, former Operation Warp Speed vaccine czar, Dr. Moncef Slaoui, issued a statement Thursday morning, as news emerged that he has resigned from additional biotech posts.
Lyell Immunopharma announced this week that it has completed construction of a $65 million, 70,000-square-foot LyFE Manufacturing Center, which the company will use to support clinical trials and meet cell therapy manufacturing needs.
Eliem Therapeutics emerged from stealth mode with $80 million in financing that will be used to develop therapeutics aimed at treating neuronal excitability disorders such as chronic pain, depression, epilepsy and anxiety.
Moncef Slaoui was fired as chairman of the board of directors of Galvani Bioelectronics following allegations of sexual harassment and inappropriate conduct.
Merck Treasurer Caroline Litchfield will become the company’s new chief financial officer. She takes over the role for Robert M. Davis, who will become company president and chief executive officer upon the retirement of current CEO Kenneth C. Frazier.
It’s March Madness in the life sciences industry, with money pouring in faster than LeBron James on a breakaway. Here’s where the big bucks went this week.
Targeted immunotherapy company Asher Bio launched today with a $55 million Series A round led by Third Rock Ventures, aiming to move its lead engineered interleukin-2 (IL-2) therapy into human testing next year.
Zenas BioPharma announced it has launched a cross-border biopharmaceutical company based in both China and the U.S.
AlloVir and Abeona Therapeutics have both appointed new chief executive officers. Here’s a look.